Likewise to EGFR mutations, ALK rearrangement is recorded in young, non-smoking men with non-squamous histology, who are susceptible of treatment with crizotinib, an ATP-competitive, orally bioavailable ALK inhibitor, firstly employed for the treatment of eml4-alk positive NSCLC [22]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.